Armata Pharmaceuticals, Inc. focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PS03 for pneumonia.
